Faced With Illumina's Solexa Bid, Affy Says New Sequencing Shops Still too Immature to Buy | GenomeWeb
NEW YORK (GenomeWeb News) — A few days after Illumina last week said it plans to buy next-generation sequencing company Solexa, rival Affymetrix said it wasn’t about to follow suit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.